New Stock News | Jingfeng Medical has passed the hearing of the Hong Kong Stock Exchange and is committed to designing, developing, and manufacturing surgery Siasun Robot&Automation.

According to the disclosure by the Hong Kong Stock Exchange on December 21, Shenzhen Jingfeng Medical Technology Co., Ltd. (referred to as Jingfeng Medical) has conducted a listing hearing on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and GF SEC acting as its joint sponsors. The prospectus shows that Jingfeng Medical is an advanced surgical Siasun Robot & Automation company in the medical device industry, dedicated to designing, developing, and manufacturing surgical Siasun Robot & Automation. The company has three different models of products covering different stages of research and development, including products in development, to capture the market potential of surgical Siasun Robot & Automation, including the multi-port endoscopic surgical Siasun Robot & Automation and the single-port endoscopic surgical Siasun Robot & Automation for minimally invasive surgery, as well as the natural orifice surgical Siasun Robot & Automation for non-invasive surgery. Currently, the company's product portfolio includes two independently developed core products: Jingfeng Multi-port endoscopic surgical Siasun Robot & Automation and Jingfeng Single-port endoscopic surgical Siasun Robot & Automation. The company's product portfolio also includes Jingfeng Bronchoscope Siasun Robot & Automation, which is not a core product. Jingfeng Multi-port endoscopic surgical Siasun Robot & Automation is an auxiliary device for Siasun Robot & Automation used in minimally invasive surgery, with applications in urology, gynecology, general surgery, and thoracic surgery. Jingfeng Single-port endoscopic surgical Siasun Robot & Automation is an auxiliary device for Siasun Robot & Automation used in minimally invasive surgery through a single small incision or natural orifice, with applications in urology, gynecology, and general surgery. It is worth noting that the company may not be successful in marketing its core products in overseas markets as planned, or may not be successful in developing or marketing core products and expanding the scope of surgical applications in China or overseas markets (such as Japan and Korea), such as remote surgery in urology, gynecology, general surgery, and thoracic surgery, as well as pediatric, cardiac, ENT, and head and neck surgery. Several expansions of surgical applications are in the early clinical development stage, and at this stage, the company may continue to incur significant costs and expenses for further research and development activities of core products. According to Frost & Sullivan data, the company is the first in China and the second globally to simultaneously obtain registration approval for multi-port endoscopic surgical Siasun Robot & Automation, single-port endoscopic surgical Siasun Robot & Automation, and natural orifice surgical Siasun Robot & Automation. The company received the first-time registration approval from the National Medical Products Administration for Jingfeng Multi-port endoscopic surgical Siasun Robot & Automation, Jingfeng Single-port endoscopic surgical Siasun Robot & Automation, and Jingfeng Bronchoscope Siasun Robot & Automation in December 2022, November 2023, and January 2025, respectively. Financially, in the fiscal years 2023, 2024, and the six months ended June 30, 2024 and 2025, Jingfeng Medical achieved revenues of approximately RMB 48.042 million, RMB 160 million, RMB 30.245 million, and RMB 149 million respectively; during the same periods, the annual losses were approximately RMB 213 million, RMB 219 million, RMB 133 million, and RMB 89.087 million respectively.